- Home
- IMUX vs ZTEK Comparison
IMUX vs ZTEK Comparison
Compare IMUX & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- ZTEK
- Stock Information
- Founded
- IMUX 2016
- ZTEK 2008
- Country
- IMUX United States
- ZTEK Canada
- Employees
- IMUX N/A
- ZTEK N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- ZTEK Major Chemicals
- Sector
- IMUX Health Care
- ZTEK Industrials
- Exchange
- IMUX Nasdaq
- ZTEK Nasdaq
- Market Cap
- IMUX 100.0M
- ZTEK 116.6M
- IPO Year
- IMUX N/A
- ZTEK N/A
- Fundamental
- Price
- IMUX $0.95
- ZTEK $1.18
- Analyst Decision
- IMUX Strong Buy
- ZTEK
- Analyst Count
- IMUX 6
- ZTEK 0
- Target Price
- IMUX $12.67
- ZTEK N/A
- AVG Volume (30 Days)
- IMUX 991.0K
- ZTEK 56.1K
- Earning Date
- IMUX 02-20-2025
- ZTEK 02-11-2025
- Dividend Yield
- IMUX N/A
- ZTEK N/A
- EPS Growth
- IMUX N/A
- ZTEK N/A
- EPS
- IMUX N/A
- ZTEK N/A
- Revenue
- IMUX N/A
- ZTEK $29,132.00
- Revenue This Year
- IMUX N/A
- ZTEK N/A
- Revenue Next Year
- IMUX N/A
- ZTEK N/A
- P/E Ratio
- IMUX N/A
- ZTEK N/A
- Revenue Growth
- IMUX N/A
- ZTEK 8.15
- 52 Week Low
- IMUX $0.95
- ZTEK $0.50
- 52 Week High
- IMUX $2.11
- ZTEK $1.48
- Technical
- Relative Strength Index (RSI)
- IMUX 36.31
- ZTEK 64.31
- Support Level
- IMUX $0.99
- ZTEK $0.95
- Resistance Level
- IMUX $1.05
- ZTEK $1.06
- Average True Range (ATR)
- IMUX 0.07
- ZTEK 0.12
- MACD
- IMUX -0.00
- ZTEK 0.01
- Stochastic Oscillator
- IMUX 1.50
- ZTEK 94.09
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.